Neuropsychiatric Associations of Apolipoprotein E Alleles in Subjects With Combat-Related Posttraumatic Stress Disorder

Data came from 54 Caucasian male veterans with combat-related posttraumatic stress disorder (PTSD) admitted consecutively to the Central Arkansas Veterans Health care System’s (CAVHS) residential PTSD treatment program. The research protocol was approved by the Human Use Committee of the University of Arkansas for Medical Sciences, and written informed consent was obtained from all subjects. All subjects were assessed using the Clinician Administered PTSD Scale (CAPS-2)⁸ and the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (SCID).⁹ APOE genotype was assessed from buccal cell samples using standard techniques¹⁰ by personnel blinded to subject diagnostic status and symptom severity. A portion of the sample-33 of the 54 subjects-also completed memory testing with the Weschler Memory Scale-Third Edition (WMS-III),¹¹ and completed testing with the Wisconsin Card Sorting Test (WCST).¹²

Average age for all subjects was 53 (SD=5.9) years. Average years of education for the sample was 11.7 (SD=2.6) years. Average total CAPS-2 score for the group was 97.3 (SD=17.9), average CAPS-2 subscale scores were as follows: CAPS-2 reexperiencing-24.3 (SD=7.4) CAPS-2 avoidance-40.1 (SD=8.7), CAPS-2 arousal-32.7 (SD=5.2). Distribution of the APOE genotype was as follows: 2/2–16.7%, 2/3–3.7%, 2/4–5.6%, 3/3–44.4%, 3/4–29.4%, 4/4–0%. In addition to meeting criteria for PTSD, 81.5% of the sample met SCID lifetime or current criteria for either major depression or dysthymic disorder, 18.5% of the sample met criteria for panic disorder, 64.8% met criteria for lifetime alcohol abuse or dependence, and 13% met criteria for lifetime substance abuse or dependence. Due to the relatively small number of subjects, we initially tested our hypothesis by comparing subjects with one APOE4 allele (2/4, 3/4) to all other subjects. No significant differences in PTSD symptoms or memory were noted between groups. However, when a comparison was made between subjects with at least one APOE2 allele (2/2, 2/3, 2/4; N=14) and the remainder of the sample (N=40), those subjects with the APOE2 allele had significantly higher CAPS-2 reexperiencing scores (29.7, compared to 22.4 ; t=3.49, p=0.001, two-tailed t test) than the remainder of the study sample, but did not differ from the remainder of the sample in terms of avoidance or arousal symptom clusters. When comparisons were made between groups given neuropsychological testing (N=33), those subjects with at least one APOE2 allele (N=9) performed significantly poorer on several of the WMS-III’s Immediate Memory scales (Logical Memory (LM): (5.5 [SD=1.1] compared to 9.5 [SD=2.9]; t=−3.69, p<0.001; Family Pictures [FP]: 6.82, SD=2.41 compared to 9.71, SD=2.22; t=−2.93, p=0.007) than the remainder of the sample, but did not differ on any of the WCST measures. In the subject sample with at least one APOE2 allele, more elevated CAPS-2 reexperiencing symptoms correlated significantly with lower FP scores (r=−0.859, p=0.013), though not with lower LM scores.

Rather than finding an association between the APOE4 allele and impaired function in this population, we found an association between possession of the APOE2 allele, more impaired memory function, and more significant reexperiencing symptoms in this group of chronic, combat-related PTSD subjects. Given the limited size of our sample and a subject population with such high levels of psychiatric comorbidity as this, these findings can be preliminary at best, but do suggest the need to further investigate the association between APOE genotype and neuropsychiatric function in this population. The isolated relationship of reexperiencing symptoms—the PTSD symptom cluster most clearly associated with memory—and impaired WMS-III scores in subjects with the APOE2 genotype suggests more significant disruptions of memory systems in these individuals.

A speculative mechanism by which APOE2 may confer impaired memory function and worsening reexperiencing symptoms would implicate the hypothalamic-pituitary-adrenal (HPA) axis and aberrant hippocampal function. Peskind and colleagues have reported that the APOE2 genotype is associated with lower cortisol in Alzheimer’s subjects and healthy controls.¹³ Low cortisol has been frequently reported in chronic, combat-related PTSD¹⁴ and there is evidence that low cortisol is associated with decreased hippocampal neuronal integrity.¹⁵ Further study in larger populations with the addition of neuroimaging techniques to study hippocampal structure and biochemistry in relationship to APOE genotype appears warranted.